So far BREO and it tag alongs are FLOPS!

Some of you don't live in a reality.

Take whatever market share from Breo and what the rest of the market for copd/asthma has. Then look up your managed care plans, mmit or any formulary search can show you accuracy.

Take a look at what coverages are now in a favorable market place with insurance playing along. Advair will be 100% covered by all and way cheaper to all parties involved. Then breo will have to pay a ton of cash to even be in the same league which it will never come close. T3 pa or non preferred.

GSK loses the advair bargaining chip and the reality will be felt instantly. All asthma and copd will go through generic advair.

 

Okay. I guess all is lost and you need to quit now and take that job at the mall. Good luck in your new career in retail sales!

 

Hey, if better comes along take it.

-No advair=no access
-Generic advair = formulary hits
-Triple therapy is no savior, has hurdles to clear. Also competition with that.
-Inventiv reps looks a lot cheaper than GSK hired reps.
-Three teams use advair for access, asthma, copd, and nucala. Two have "merged" while diabetes has struggled and we cut managers.
-Using advair for deals on current drug access takes hit too.

So positives!!!!!

 

CSO's are going to replace you all!!

 

The scramble to re org may result in that. Reading other boards there are constantly cuts in this dying field and every seems to use a third party company.